Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.
Matti S. Aapro, MD, of IMO Clinique de Genolier, offered a case presentation and a cross-disciplinary approach to finding the best way to effect a cure with minimal impact on quality of life.
Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.
